Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000922 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro
A Phase 2 study of Diabetes Mellitus, sponsored by Biodel.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01000922 is a Phase 2 study of Diabetes Mellitus that has completed, run by Biodel. The registered enrollment target is 24 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01000922, a Phase 2 study of Diabetes Mellitus, has completed, sponsored by Biodel.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.
Conditions Studied
Interventions
- DRUG Lispro
- DRUG Regular Human Insulin
- DRUG VIAject
- DRUG VIAject 50%
- DRUG VIAject/Insulin Glargine
Study Locations (1)
California
- Profil Institute for Clinical Research, Inc. (PICR) - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000922
The ClinicalTrials.gov registry entry for NCT01000922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is Biodel, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 5 interventions - of which Lispro is the first listed.
NCT01000922 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01000922 about?
NCT01000922 is a clinical study titled "A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro". Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.
What is the current status of trial NCT01000922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2006-06. Estimated completion is 2008-01.
What conditions does trial NCT01000922 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT01000922?
The interventions under investigation include: Lispro (DRUG), Regular Human Insulin (DRUG), VIAject (DRUG), VIAject 50% (DRUG), VIAject/Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT01000922?
This trial is sponsored by Biodel, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01000922 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
RECRUITING · Phase 2
-
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.